医師の一分

アクセスカウンタ

zoom RSS 医薬品企業が医師に支払った金額の公表が義務化/米国医療事情

<<   作成日時 : 2012/01/20 20:13   >>

なるほど(納得、参考になった、ヘー) ブログ気持玉 3 / トラックバック 0 / コメント 0

医薬品企業が医師に支払った金額の公表が義務化/米国医療事情
 オバマ政権は、医学的利益相反を阻止するために製薬会社が医師に研究・コンサルティング・講演・旅行・娯楽に対しての支払いを公表する態勢を整えている。
 こうした支払いが医師の治療決定に影響を与え、より高価な医薬品や医療機器の使用を促進して医療費の高騰に貢献している可能性がある証拠が出てきている。
 多くの医師が、アドバイスや講演の見返りに時には年に数千ドルから数百万ドルを製薬会社や医療機器会社から受け取っている。ニューヨークタイムズなどによる分析では、医師の約1/4が現金支払いを受け、ほぼ2/3がスタッフや自分の昼夕食を含めた日常的な贈答を受けている。
 新たな基準では、医師へのすべての支払いを開示する必要がある。
 タイムズ紙によれば、金銭を受け取っている医師は、子どもへの強力な向精神薬を処方するといった、危険を伴う未承認の方法で処方しやすいという。
 新たな基準では、メディケアやメディケイドでカバーされる製品が一つでもある会社は、従業員以外の医師へのすべての支払いを開示する必要がある。連邦政府はウェッブ上で公開する予定である。
 処方薬と機器のメーカーは、開発に役立つ評価や新製品促進のために医師に支払っている場合は報告する必要がある。1,100以上の企業に報告義務が生じると政府は考えている。報告しないと1万ドル以内の罰金、故意に報告しないと1件につき最大10万ドル、年間最大100万ドルとなる。

----------------------------------------------------
U.S. to Force Drug Firms to Report Money Paid to Doctors
By ROBERT PEAR
Published: January 16, 2012
http://www.nytimes.com/2012/01/17/health/policy/us-to-tell-drug-makers-to-disclose-payments-to-doctors.html

WASHINGTON ? To head off medical conflicts of interest, the Obama administration is poised to require drug companies to disclose the payments they make to doctors for research, consulting, speaking, travel and entertainment.

Many researchers have found evidence that such payments can influence doctors’ treatment decisions and contribute to higher costs by encouraging the use of more expensive drugs and medical devices.

Consumer advocates and members of Congress say patients may benefit from the new standards, being issued by the government under the new health care law. Officials said the disclosures increased the likelihood that doctors would make decisions in the best interests of patients, without regard to the doctors’ financial interests.

Large numbers of doctors receive payments from drug and device companies every year ? sometimes into the hundreds of thousands or millions of dollars ? in exchange for providing advice and giving lectures. Analyses by The New York Times and others have found that about a quarter of doctors take cash payments from drug or device makers and that nearly two-thirds accept routine gifts of food, including lunch for staff members and dinner for themselves.

The Times has found that doctors who take money from drug makers often practice medicine differently from those who do not and that they are more willing to prescribe drugs in risky and unapproved ways, such as prescribing powerful antipsychotic medicines for children.

Under the new standards, if a company has just one product covered by Medicare or Medicaid, it will have to disclose all its payments to doctors other than its own employees. The federal government will post the payment data on a Web site where it will be available to the public.

Manufacturers of prescription drugs and devices will have to report if they pay a doctor to help develop, assess and promote new products ? or if, for example, a pharmaceutical sales agent delivers $25 worth of bagels and coffee to a doctor’s office for a meeting. Royalty payments to doctors, for inventions or discoveries, and payments to teaching hospitals for research or other activities will also have to be reported.

The Obama administration estimates that more than 1,100 drug, device and medical supply companies will have to file reports, generating “large amounts of new data.” Federal officials said they would inspect and audit drug company records to make sure the reports were accurate and complete.

Companies will be subject to a penalty up to $10,000 for each payment they fail to report. A company that knowingly fails to report payments will be subject to a penalty up to $100,000 for each violation, up to a total of $1 million a year.

Top executives are potentially liable because a senior official of each company ? the chief executive, chief financial officer or chief compliance officer ? must attest to the accuracy of each report.

The new requirements, or something very similar, will take effect soon; in fact, they are overdue. Under the new health care law, the administration was supposed to establish payment-reporting procedures by Oct. 1, 2011. The public will have until Feb. 17 to comment on the proposals, which are broadly consistent with the expectations of industry and consumer groups. After considering the comments, Medicare officials will issue final rules with the force of law.

Consumer advocates have long demanded details of the financial ties between doctors and drug and device companies.

Allan J. Coukell, a pharmacist and consumer advocate at the Pew Charitable Trusts, said: “Patients want to know they are getting treatment based on medical evidence, not a lunch or a financial relationship. They want to know if their doctor has a financial relationship with a pharmaceutical company, but they are often uncomfortable asking the doctor directly.”

In an introduction to the proposed rules, the Obama administration says that patients can benefit when doctors and the industry work together to develop life-saving drugs and devices. But, it said, these relationships can also “lead to conflicts of interests that may affect clinical decision-making” and “threaten the underlying integrity of the health care system.”

The administration does not try to define the difference between proper and improper payments. It says simply that public reporting of the financial ties between doctors and drug and device companies “will permit patients to make better-informed decisions when choosing health care professionals and making treatment decisions.”

The new standards carry out legislation championed by Senators Charles E. Grassley, Republican of Iowa, and Herb Kohl, Democrat of Wisconsin. The legislation was included in the 2010 health care overhaul.

“The goal is to let the sun shine in and make information available to foster accountability,” Mr. Grassley said.

Christopher L. White, executive vice president of the Advanced Medical Technology Association, which represents makers of medical devices, said the payment data could be used by federal law enforcement agencies, plaintiffs’ lawyers and whistleblowers.

“Some companies fear that doctors may no longer want to engage in consulting arrangements, and such reluctance could chill innovation,” Mr. White said.

Matthew D. Bennett, a senior vice president of the Pharmaceutical Research and Manufacturers of America, said the industry “supported transparency of physician payment information.” However, he said, it is important that payment data be presented in a proper context, emphasizing that interactions between doctors and drug companies played a critical role in improving care, educating doctors and fostering appropriate use of medicines.

Medicare and Medicaid, the programs for older Americans, the disabled and the poor, spend more than $100 billion a year on drugs and devices.

Although the Congressional Budget Office does not predict immediate savings, it has said that, “over time, disclosure has the potential to reduce spending,” by reducing instances of overprescribing.

The law also requires drug and device companies to report the amount of “any ownership or investment interest” held by doctors or their immediate family members, other than holdings of publicly traded stocks.

The administration intends to apply the same disclosure requirements to doctor-owned companies that distribute medical devices. Such companies allow doctors to benefit financially from sales of devices they use in surgery.

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ
気持玉数 : 3
なるほど(納得、参考になった、ヘー) なるほど(納得、参考になった、ヘー)
驚いた

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
医薬品企業が医師に支払った金額の公表が義務化/米国医療事情 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる